A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

To join this study, your doctor would need to confirm you have a specific type of bile duct cancer (adenocarcinoma) that has been identified through a tissue sample. The cancer must be advanced, meaning it has either spread to other parts of your body or can't be removed surgically, and you must not have had any previous treatment for this advanced stage of your cancer.

You also need to be generally well enough to take part, as measured by a doctor's assessment (called an ECOG Performance Status of 0 or 1). Your body's organs, like your blood, liver, and kidneys, need to be working well. Additionally, your doctor will need a recent scan showing that your cancer can be measured accurately.

There are also some reasons why you might not be able to join. For example, if you have a specific type of bile duct cancer called ampullary carcinoma, you wouldn't be eligible. Also, if you have had certain immune system disorders, serious gut problems causing diarrhea, or active skin conditions requiring strong ongoing treatment, or certain lung conditions, you wouldn't be able to participate.

If you decide to join this study, you will be given one of the two treatment combinations. Doctors will monitor your health closely throughout. This will involve regular visits to the clinic for medical examinations, blood tests, and scans (like CT or MRI) to see how the treatment is working and check for any side effects. You will receive the study medication as prescribed by the research team. The total length of your participation will depend on how you respond to the treatment and the study plan, but you will have follow-up appointments even after active treatment ends. The research team will explain the full schedule of visits and assessments to you.